Redcliffe Lifetech (Redcliffe), an omnichannel diagnostics platform, has raised $61 million in a Series B round led by LeapFrog Investments and including Healthquad, Schroders, LC Nueva, Growth Spark Ventures, and existing investors Chiratae Ventures and Alkemi Venture Partners.
Redcliffe was founded in 2018 and provides diagnostic services through its network of 22 labs in 14 locations, several of which are NABL-accredited, according to the company.
The funds will be used to expand Redcliffe’s geographic reach across India, with a particular focus on bringing its low-cost, high-quality direct-to-consumer diagnostics to tier 2, 3, and 4 cities. The cash would enable it to provide millions of homes with affordable, quick, and convenient pathology services ranging from glucose to genetics.
The money will also go into expanding Redcliffe’s platform and expanding its product offerings to include imaging, disease data profiling, and lifestyle management. This would assist it achieve its goal of shifting India’s healthcare focus away from treatment and toward early detection and prevention.